All In MedTech

PMA device

Trilogy Transcatheter Heart Valve System

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

3

Breakthrough-designated

Device trials

27

Naming "Trilogy"

MAUDE reports

55,426

Brand "Trilogy", since 2015

PubMed studies

858

Mentioning "Trilogy"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Trilogy Transcatheter Heart Valve System

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 3 of 3 decisions filed under this name.

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Trilogy", any status and sponsor, newest update first.

Open in Trial Radar
  • JenaValve Technology, Inc.Not on our public-company list

    NCT06608823 · 1,016 participants (planned) · Start Jun 18, 2025 · Primary completion Jun 2027

    Device: Transcatheter Aortic Valve Replacement (TAVR) using Trilogy THV System; SAVR · For: Aortic Regurgitation; Aortic Valve Insufficiency; Aortic Insufficiency

    Sites: Burlingame, California; La Jolla, California; Los Angeles, California · 40 sites in all

  • JenaValve Technology, Inc.Not on our public-company list

    NCT06594705 · 50 participants · Start Dec 9, 2024 · Primary completion Aug 9, 2026

    Device: JenaValve Trilogy Heart Valve System · For: Aortic Regurgitation; Aortic Valve Insufficiency; Aortic Insufficiency and 2 more

    Sites: Los Angeles, California; San Francisco, California; Washington D.C., District of Columbia · 14 sites in all

  • Philips RespironicsPublic (PHG)

    NCT00810498 · 11 participants · Start Mar 12, 2008 · Primary completion Feb 5, 2009

    Device: Trilogy; Standard of Care · For: Respiratory Insufficiency; Respiratory Failure

    Sites: Winnipeg, Canada

24 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Trilogy", and for the whole product code for context.

This brand

55,426 reports: 53,004 malfunction, 1,896 injury, 490 death

Whole product code NPT

77,669 reports: 12,243 malfunction, 57,723 injury, 7,693 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

Published research

The most relevant PubMed records for "Trilogy"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code NPT.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.